	Application No.		Applicant(s)
Notice of Allowability	09/709,103		CISMOWSKI ET AL.
	Examiner		Art Unit
	Daniel M Sullivan		1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to *the amendment filed 28 August 2003*.

2. ☒ The allowed claim(s) is/are *81-93*.

3. ☒ The drawings filed on *08 November 2000* are accepted by the Examiner.

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

    a) ☐ All   b) ☐ Some*   c) ☐ None   of the:

       1. ☐ Certified copies of the priority documents have been received.

       2. ☐ Certified copies of the priority documents have been received in Application No. _____ .

       3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

    * Certified copies not received: _____ .

5. ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

    (a) ☐ The translation of the foreign language provisional application has been received.

6. ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. **THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

7. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

8. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.

    (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached

        1) ☐ hereto or 2) ☐ to Paper No. ____ .

    (b) ☐ including changes required by the proposed drawing correction filed _____ , which has been approved by the Examiner.

    (c) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. _____ .

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).

9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1 ☐ Notice of References Cited (PTO-892)

2 ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)

3 ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No. _____

4 ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material

5 ☐ Notice of Informal Patent Application (PTO-152)

6 ☒ Interview Summary (PTO-413), Paper No. _____ .

7 ☒ Examiner's Amendment/Comment

8 ☐ Examiner's Statement of Reasons for Allowance

9 ☐ Other   .

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or

additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR

1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the

payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with

Gary Gershik on 10 November 2003.

The application has been amended as follows:

In the specification

Please replace the first and second paragraphs on page 6 with the following:

--*Figures 4A and 4B* depict the alignment of AGS with representatives of all major

classes of small G proteins in humans indicating that AGS is likely to be the founding member of

a novel class of small G proteins in humans. The polypeptide sequences correspond to the

following: C-HA-RAS1 (SEQ ID NO:47); RALA (SEQ ID NO:48); RAB-1A (SEQ ID NO:49);

RHOHP1 (SEQ ID NO:50); CDC42 (SEQ ID NO:51); RAC2 (SEQ ID NO:52); ARL1 (SEQ ID

NO:53); RND3/RHOE (SEQ ID NO:54); AGS1 (SEQ ID NO:2).

Figure 5 depicts the alignment of residues in the P region and in the G* region of various

small G proteins. Asterisks indicate the location of three highly conserved residues that are

altered in AGS, Rnd1, Rnd2 and Rnd3. The polypeptide sequences correspond to the following:

RhoE/Rnd3 P REGION (SEQ ID NO:55), G* REGION (SEQ ID NO:64); Rnd2 P REGION

(SEQ ID NO:56), G* REGION (SEQ ID NO:65); Rnd1 P REGION (SEQ ID NO:57), G*

REGION (SEQ ID NO:66); RhoA P REGION (SEQ ID NO:58), G' REGION (SEQ ID NO:67);

RhoB P REGION (SEQ ID NO:59), G' REGION (SEQ ID NO:68); Cdc42 P REGION (SEQ ID

NO:60), G' REGION (SEQ ID NO:69); Rac1 P REGION (SEQ ID NO:61), G' REGION (SEQ

ID NO:70); H-ras P REGION (SEQ ID NO:62), G' REGION (SEQ ID NO:71); AGS P

REGION (SEQ ID NO:63), G' REGION (SEQ ID NO:72). Numbers indicate the positions of the

amino acid sequence of AGS.--

In the claims

Please amend claims 84 and 91 as follows:

84. An isolated nucleic acid comprising nucleotides having a sequence encoding ~~the same~~

an AGS protein, which is encoded by the sequence set forth in SEQ ID NO:1 or the sequence set

forth in SEQ ID NO:3, or a full complement to the isolated nucleic acid.

91. An isolated host cell containing the vector of claim 89.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Daniel M Sullivan whose telephone number is 703-305-4448.

The examiner can normally be reached on Monday through Friday 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Remy Yucel, Ph.D. can be reached on 703-305-1998. The fax phone number for the

organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703-308-0196.

DMS

DAVID G.
PRIMARY EXAMINER